Valerian for anxiety disorders
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anxiety disorders are very common mental health problems in the general population and in primary care settings. Herbal medicines are popular and used worldwide and might be considered as a treatment option for anxiety if shown to be effective and safe. OBJECTIVES: To investigate the effectiveness and safety of valerian for treating anxiety disorders. SEARCH STRATEGY: Electronic searches: The Cochrane Collaboration Depression, Anxiety and Neurosis Cochrane Controlled Trials Register (CCDANCTR-Studies and CCDANCTR-References) searched on 04/08/2006, MEDLINE, Lilacs. References of all identified studies were inspected for additional studies. First authors of each included study, manufacturers of valerian products, and experts in the field were contacted for information regarding unpublished trials. SELECTION CRITERIA: Randomised controlled trials (RCTs) and quasi-randomised trials of valerian extract of any dose, regime, or method of administration, for people with any primary diagnosis of general anxiety disorder, anxiety neurosis, chronic anxiety status, or any other disorder in which anxiety is the primary symptom (panic disorder, obsessive compulsive disorder, social phobia, agoraphobia, other types of phobia, postraumatic stress disorder). Effectiveness was measured using clinical outcome measures and other scales for anxiety symptoms. DATA COLLECTION AND ANALYSIS: Two review authors independently applied inclusion criteria, extracted and entered data, and performed the trial quality assessments. Where disagreements occurred, the third review author was consulted. Methodological quality of included trials was assessed using Cochrane Handbook criteria. For dichotomous outcomes, relative risk (RR) was calculated, and for continuous outcomes, the weighted mean difference (WMD) was calculated, with their respective 95% confidence intervals. MAIN RESULTS: One RCT involving 36 patients wih generalised anxiety disorder was eligible for inclusion. This was a 4 week pilot study of valerian, diazepam and placebo. There were no significant differences between the valerian and placebo groups in HAM-A total scores, or in somatic and psychic factor scores. Similarly, there were no significant differences in HAM-A scores between the valerian and diazepam groups, although based on STAI-Trait scores, significantly greater symptom improvement was indicated in the diazepam group. There were no significant differences between the three groups in the number of patients reporting side effects or in dropout rates. AUTHORS' CONCLUSIONS: Since only one small study is currently available, there is insufficient evidence to draw any conclusions about the efficacy or safety of valerian compared with placebo or diazepam for anxiety disorders. RCTs involving larger samples and comparing valerian with placebo or other interventions used to treat of anxiety disorders, such as antidepressants, are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Bijl, R. V., Ravelli, A., & van Zessen, G. (1998) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s001270050098 · Cited by 1,216
Quality of Life in Individuals With Anxiety Disorders
Mendlowicz, M. V., & Stein, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.669 · Cited by 955
Borkovec, T. D., & Costello, E. (1993) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.61.4.611 · Cited by 756
Gould, R. A., Otto, M. W., Pollack, M. H., & Yap, L. (1997) · Behavior Therapy · doi:10.1016/s0005-7894(97)80048-2 · Cited by 352
Psychological therapies for generalised anxiety disorder
Hunot, V., Churchill, R., Teixeira, V., & Silva de Lima, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001848.pub4 · Cited by 315
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Cochrane meta-analyses found two studies of passiflora (passion flower) indicating it was as effective as benzodiazepines (Level 2) [633], and one study of valerian which found no significant differences between placebo, valerian, or diazepam (Level 2, negative) [634,635].”
BackgroundKennedy, D. O., & Wightman, E. L. (2011) · Advances in Nutrition · doi:10.3945/an.110.000117 · Cited by 684
Traditional use and safety of herbal medicines1
Moreira, D. D. L., Teixeira, S. S., Monteiro, M. H. D., De-Oliveira, A. C. A. X., & Paumgartten, F. J. R. (2014) · Revista Brasileira de Farmacognosia · doi:10.1016/j.bjp.2014.03.006 · Cited by 266
Herbal medicines in the treatment of psychiatric disorders: a systematic review
Sarris, J. (2007) · Phytotherapy Research · doi:10.1002/ptr.2187 · Cited by 164
Medicinal herbs for the treatment of anxiety: a systematic review and network meta-analysis
Zhang, W., Yan, Y., Wu, Y., Yang, H., Zhu, P., Yan, F., Zhao, R., Tian, P., Wang, T., Fan, Q., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106204 · Cited by 75
Metadata
- Authors
- Miyasaka, L. S., Atallah, Á. N., & Soares, B.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2006-10-18
- Issue
- 4
- Pages
- CD004515-CD004515
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1985896561
- Cited by
- 135
- References
- 6
- FWCI
- 12.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Valerian for anxiety disorders. https://app.cochat.ai/papers/10.1002/14651858.cd004515.pub2
- The paper
- Miyasaka, L. S., Atallah, Á. N., & Soares, B. (2006). Valerian for anxiety disorders. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004515.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.